Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Real-life First Dose Effect of Fasenra in Patients With Severe Uncontrolled Asthma

NCT04200326 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT04200326
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04200326 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Real-life First Dose Effect of Fasenra in Patients With Severe Uncontrolled Asthma
Lead sponsor
AstraZeneca
Phase
Observational
Overall status
Completed
Start date
December 20, 2019
Completion date
April 9, 2020
Enrollment
5 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

severe uncontrolled asthma